SS-31 acts directly at the mitochondrial level, supporting cellular energy production and reducing reactive oxygen species formation.
It is studied in ageing, cardiovascular dysfunction, neurodegenerative conditions, and metabolic diseases.
• Supports mitochondrial energy production
• Reduces oxidative stress
• Improves cellular ATP output
• Supports cardiovascular function
• May enhance muscle endurance
• Supports brain mitochondrial health
• Promotes cellular resilience
• Supports recovery from metabolic stress
• May improve exercise tolerance
• Contributes to healthy aging processes
SS-31 has been evaluated in multiple clinical and translational studies targeting mitochondrial dysfunction. Research demonstrates improved mitochondrial bioenergetics and reduced oxidative damage.
Studies in cardiovascular and skeletal muscle models show improved mitochondrial efficiency and cellular performance. Human trials suggest improved mitochondrial function markers without major adverse effects.
Dosage and Administration of SS-31 (10 mg / 2 ml):
• Recommended dose: 2.5 mg daily
• Correct dose in units: 50 units daily
• Frequency & course duration: Daily for 2–4 weeks
• Pause: 4 weeks break
• 1 unit = 0.05 mg (50 mcg)
• 50 units = 2.5 mg
One SS-31 pen lasts approximately 4 days.
For a 2–4 week cycle:
• 2 weeks (14 days) → 4 pens
• 4 weeks (28 days) → 7 pens
Apply to recommended area. Rotate application sites. Hold the device in place for 10 seconds before removal.
Peptides Commonly Combined with SS-31
• MOTS-C – mitochondrial metabolic support
• BPC-157 – tissue repair synergy
• NAD+ precursors – cellular energy enhancement
• GHK-Cu – regenerative support
• Mild injection site discomfort
• Temporary fatigue during adaptation phase
• Mild headache
Generally well tolerated in studied doses.
This compound is intended strictly for research and observation purposes only. The information provided is not medical advice and is not intended to diagnose or treat any condition.